Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02802553
Other study ID # CASE4116
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 28, 2017
Est. completion date December 2024

Study information

Verified date June 2024
Source Case Comprehensive Cancer Center
Contact Stephanie A Valente, DO
Phone 1-866-223-8100
Email TaussigResearch@ccf.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot study to test and characterize the ability of the Smart Goggles system to detect fluorescently labeled sentinel lymph nodes (SLNs). Specifically, this study will test the sensitivity and specificity of the Smart Goggles to detect indocyanine green (ICG) accumulation in sentinel lymph nodes of breast cancer patients after peritumoral injection of ICG (Cardio-GreenTM), under standard-of-care application conditions.


Description:

Primary Objective -Positive fluorescence signal in SLNs imaged by the Smart Goggles system. Secondary Objectives - Confirmation of ICG within lesions per histologic tissue exam by SLN biopsy. - Comparison of lesions detected by the Smart Goggles vs. lesions detected using SPY/Quest/PDE vs. gold standard of gamma probe and blue dyes. Exploratory Objectives -Collection of preliminary data for a future, powered study for lymphatic mapping in breast cancer Study Design This is an unpowered pilot study to determine the sensitivity of the new Smart Goggles device, for detection of ICG fluorescence in SLNs of breast cancers in a clinical setting. The investigators have chosen to examine ICG as the contrast agent and breast cancer as the clinical target, because this agent is FDA-approved and is regularly used for lymphatic mapping (skin cancers). The study team will be applying ICG for the same length of time as the standard-of-care procedures including radiotracers and blue dyes. The study involves a single visit, lasting ~3-4 hours total. Multiple SLN biopsies will be performed if multiple SLNs are identified.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects with at least 1 lesion of tumor of the breast - Subjects must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Subjects who have been treated with radiation therapy on the chest. - Has had previous sentinel lymph node biopsy - Has a known hypersensitivity to ICG, methylene blue and 99mTc-colloid.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Smart Goggle
Smart Goggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The Smart Goggles is a non-invasive imaging system that does not require contact with patients.
Other:
Cardio-Green
Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
Device:
SPY Elite Imaging system
Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
Quest near-infrared (NIR) Imaging system
Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
PDE Imaging system
Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
Gamma probe
Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
Other:
Blue Dyes
Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.

Locations

Country Name City State
United States Cleveland Clinic, Case Comprehensive Cancer Center Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
Case Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Binary response of the number of participants in which the Smart Goggles identifies the same Sentinel Lymph Nodes (SLN) within each participant as those identified by the gamma probe and blue dyes gold standard. Agreement on 6 consecutive participants would occur less than 2% of the time by random chance (p = 0.56 = 0.016). If the two methods agree on all 6 participants, the current protocol will end successfully. However, if the two methods fail to agree on the SLN once among the first 6 participants, enrollment will continue to 25 participants or until a second failed agreement occurs. At the end of the procedure, about 50 minutes
Secondary Binary response of the number of participants in which the Smart Goggles identifies the same Sentinel Lymph Nodes (SLN) within each participant as those identified by the SPY/Quest/PDE imaging systems. A commercial imaging system that measures fluorescence output of ICG will be used to measure the near infrared fluorescence in vivo. Measurements are painless and involve no risk to the participant. The measurements are non-contact and recorded by a computer; each measurement is painless and takes 10 seconds. The signal is calibrated against known fluorescence standards, and the relative amount of ICG in a given measurement is interpolated from the standard curve. At the end of the procedure, about 50 minutes
Secondary Number of samples with ICG detected in biopsy tissue Confirmation of ICG within lesions per histologic tissue exam by SLN biopsy. At the end of the procedure, about 50 minutes
Secondary Number of samples with lymph node detected in biopsy tissue Confirmation of lymph node tissue within lesions per histologic tissue exam by SLN biopsy. At the end of the procedure, about 50 minutes
Secondary Fluorescence intensity Fluorescence intensity will be compared for the removed lymph nodes between the Smart Goggles and the standard used fluorescent imaging technology. Intensity will be reported in Arbitrary units
ยท
Typically no more than 30 minutes
Secondary Number of removed lymph nodes with cancer cells Standard histological analyses will be performed on the biopsy specimens. Presence of absence of cancer cells in the removed lymph nodes will serve as the source of specificity. At the end of the procedure, about 50 minutes
Secondary Sensitivity as measured via the ICG accumulation curve The ICG accumulation curve generated from each device (Smart Goggles vs previously validated fluorescence imaging systems), measured on the same SLN, will be used to characterize the relative sensitivity of the Smart Goggles for ICG detection in vivo. At the end of the procedure, about 50 minutes
Secondary Specificity as measured via the ICG accumulation curve The ICG accumulation curve generated from each device (Smart Goggles vs previously validated fluorescence imaging systems), measured on the same SLN, will be used to characterize the relative specificity of the Smart Goggles for ICG detection in vivo. At the end of the procedure, about 50 minutes
Secondary Number of surgeons who prefer interventional device vs current near-infrared (NIR) cameras Surgeons preference for using the Googles for ICG detection versus the current near-infrared NIR cameras At the end of the procedure, about 50 minutes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03595592 - Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer Phase 3
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT06158217 - Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT02773784 - Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
Recruiting NCT01509781 - Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Phase 3
Completed NCT04478669 - Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
Recruiting NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Phase 2
Recruiting NCT04677816 - Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Phase 2
Terminated NCT01934335 - Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer Phase 2
Completed NCT00507611 - Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients N/A
Completed NCT00581750 - Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Completed NCT03304171 - Overall Diet Quality and Breast Cancer Risk N/A
Completed NCT03709186 - Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
Terminated NCT03361800 - Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Early Phase 1
Recruiting NCT04648904 - Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer Early Phase 1
Recruiting NCT06328465 - fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases N/A
Active, not recruiting NCT03109522 - Axillary Reverse Mapping (ARM) Technique N/A
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Recruiting NCT03497702 - Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer Phase 2